# NIH Reporter #2R44DK122903-03A1

A FIRST IN CLASS TREATMENT FOR LIVER CIRRHOSIS

**Recipient:** XFIBRA, INC.

**Award Amount:** $1,188,325.00
**Ceiling:** $1,188,325.00

**Awarded:** September 07, 2026

**Identifier:** 2R44DK122903-03A1

NIH/NIDDK awarded a grant to XFIBRA, INC. for developing a novel treatment for liver cirrhosis, including preclinical toxicology studies of drug candidate XFB19.

### Description

A grant opportunity for a project focused on developing a first-in-class treatment for liver cirrhosis, supported by the NIH/NIDDK. The project involves long-term preclinical toxicology studies of a drug candidate named XFB19, aimed at supporting future clinical trials.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11406381)